加载中
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.
前收盘价
US$11.00
+US$0.14 · +1.29%
盘中时间采用ET。市场数据可能有所延迟。
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.
日内区间
当前US$11.00
52周区间
当前US$11.00
盘中时间采用ET。市场数据可能有所延迟。
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.
日内区间
当前US$11.00
52周区间
当前US$11.00
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$27.17
上涨空间 147.00%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1876.46万0.00%2.3万亿 USD0.03%US$381.94+0.63%
State Street SPDR S&P Biotech ETFXBI1184.54万0.12%98.74亿 USD0.35%US$153.77+3.00%
iShares Russell 2000 ETFIWM1059.3万0.01%787.4亿 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF414.05万0.00%954亿 USD0.05%US$235+0.80%
Vanguard Russell 2000 ETFVTWO278.41万0.02%180亿 USD0.06%US$112.66+0.50%
Schwab U.S. Small-Cap ETFSCHA228.61万0.01%218.24亿 USD0.03%US$32.79+0.40%
Dimensional - US Small Cap ETFDFAS191.35万0.01%338.69亿 USD0.31%US$78.35+0.32%
Fidelity Fundamental Small-Mid Cap ETFFFSM187.79万0.12%14.4亿 USD0.43%US$34.13+0.62%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHADimensional - US Small Cap ETFDFASFidelity Fundamental Small-Mid Cap ETFFFSMAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
